// App-Quantinova.ai

OP032 : Everolimus-eluting bioresorbable scaffold as a treatment option for patients with in-stent restenosis: insights from the multicentre GHOST-EU registry

Researchers

Presenter

  • Wiebe J

Principal Investigators

  • Gori T

  • Araszkiewicz A

  • Geraci S

  • Pyxaras S

  • Mattesini A

  • Naganuma T

  • Munzel T

  • Tamburino C

  • Nef H

  • Latib A

  • Mehilli J

  • Lesiak M

  • Caramanno G

  • Naber C

  • Di Mario C

  • Colombo A

  • Boeder N

Medical Centers

  • Ferrarotto Hospital, University of Catania, Catania, Italy

  • San Giovanni di Dio Hospital, Agrigento, Italy

  • Department of Cardiology, Klinikum Grosshadern, Ludwig- Maximilian Universitat, Munchen, Germany

  • EMO GVM Centro Cuore Columbus/San Raffaele Hospital, Milan, Italy

  • National Institute of Health Research Cardiovascular BRU, Royal Brompton Hospital & Imperial College, London, United Kingdom

  • Department of Hematology, Poznan University of Medical Sciences, Poznan,

  • Klinik fur Kardiologie und Angiologie, Elisabeth-Krankenhaus, Essen, Germany

  • University of Giessen, Giessen, Germany

  • Medizinische Klinik und Poliklinik, Universitatsmedizin Mainz, Mainz, Germany

Locations

  • Poland

  • Germany

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Stable coronary artery disease

  • Acute Coronary Syndromes

  • Coronary Artery Disease

  • Myocardial infarction

  • Restenosis

  • Hypertension

  • Venous thrombosis

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved